Table 1. Summary of select trials with targeted single agents in relapsed/refractory PTCL.
| Agent | Class | Subtype | Trial
phase |
n | Median
follow- up |
ORR | CR | Median
PFS |
Median
OS |
Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Pralatrexate | Antifolate | PTCL | II | 111 | 18
months |
29% | 11% | 3.5
months |
14.5
months |
36 |
| Romidepsin | HDAC
inhibitor |
PTCL | II | 130 | 22.3
months |
25% | 15% | 4
months |
11.3
months |
40 |
| Romidepsin | HDAC
inhibitor |
PTCL | II | 45 | — | 38% | 18% | — | — | 41 |
| Belinostat | HDAC
inhibitor |
PTCL | II | 129 | — | 25.8% | 10.8% | 1.6
months |
7.9
months |
42 |
| Chidamide | HDAC
inhibitor |
PTCL | II | 83 | 29
months |
28% | 14% | 2.1
months |
21.4
months |
43 |
| Brentuximab
vedotin |
Anti-CD30
antibody drug conjugate |
ALCL | II | 58 | 71.4
months |
86% | 57% | 20
months |
Not
reached |
44, 54 |
| Crizotinib | Tyrosine
kinase inhibitor |
ALK-
positive ALCL |
II | 9 | — | 90.9% | 100% | — | — | 47 |
| Duvelisib | PI3K-δ
and PI3K-γ inhibitor |
PTCL | I | 16 | — | 50% | 19% | 8.3
months |
8.4
months |
48 |
| Mogamulizumab | Anti-CCR4
antibody |
CCR4-
positive PTCL |
II | 29 | — | 34% | 17% | 2.0
months |
14.2
months |
51 |
| Nivolumab | Anti-PD-1
antibody |
PTCL | I | 5 | 44
weeks |
40% | 0 | 14
weeks |
— | 55 |
Abbreviations: ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; CCR4, CC chemokine receptor 4; CR, complete response; HDAC, histone deacetylase inhibitor; ORR, objective response rate; OS, overall survival; PD-1, programmed death-1; PFS, progression-free survival; PI3K, phosphatidylinositol 3-kinase; PTCL, peripheral T-cell lymphoma.